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Abstract
OBJECTIVE: To find previously unknown properties of ML3000, a competitive inhibitor of the
cyclooxygenase and the lipoxygenase (LO) pathway. METHODS: Gene expression of ML3000 treated
and untreated rheumatoid arthritis synovial fibroblasts were measured with Affymetrix gene arrays.
Downregulation of chemokine (C-X-C motif) ligands CXCL9, CXCL10 and CXCL11 was verified with
Real-time polymerase chain reaction, CXCL10 protein levels were determined with ELISA.
Rheumatoid arthritis synovial fibroblasts were treated with the cyclooxygenase inhibitor naproxen, the
5-LO inhibitor BWA4C and the 5-lipoxygenase-activating protein (FLAP) inhibitor MK886, and
consecutive changes in CXCL10 protein levels measured. 5-LO expression was determined by
polymerase chain reaction and Western blot. RESULTS: In synovial fibroblasts and monocyte-derived
macrophages ML3000 inhibited the tumour necrosis factor induced expression of CXCL9, CXCL10 and
CXCL11, which are all ligands of the chemokine receptor CXCR3. No effect was observed in
monocytes. Whereas inhibition of the cyclooxygenase pathway or the FLAP protein showed no effect,
blockade of 5-LO significantly downregulated CXCL10 protein levels. 5-LO mRNA was detected in
monocytes and in monocyte-derived macrophages. All tested cell types expressed 5-LO protein.
CONCLUSIONS: ML3000 effectively downregulates CXCR3 ligands. This study confirms that a
thorough analysis of the impact of a drug on its target cells cannot only reveal unexpected properties of
a substance, but also helps to understand the underlying molecular mechanisms. Accordingly, our data
provide the basis for further clinical studies testing the application of ML3000 in diseases such as
rheumatoid arthritis or multiple sclerosis.
doi:10.1136/ard.2007.071589 
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Objective: To find previously unknown properties of
ML3000, a competitive inhibitor of the cyclooxygenase
and the lipoxygenase (LO) pathway.
Methods: Gene expression of ML3000 treated and
untreated rheumatoid arthritis synovial fibroblasts were
measured with Affymetrix gene arrays. Downregulation of
chemokine (C-X-C motif) ligands CXCL9, CXCL10 and
CXCL11 was verified with Real-time polymerase chain
reaction, CXCL10 protein levels were determined with
ELISA. Rheumatoid arthritis synovial fibroblasts were
treated with the cyclooxygenase inhibitor naproxen, the 5-
LO inhibitor BWA4C and the 5-lipoxygenase-activating
protein (FLAP) inhibitor MK886, and consecutive changes
in CXCL10 protein levels measured. 5-LO expression was
determined by polymerase chain reaction and Western
blot.
Results: In synovial fibroblasts and monocyte-derived
macrophages ML3000 inhibited the tumour necrosis
factor induced expression of CXCL9, CXCL10 and CXCL11,
which are all ligands of the chemokine receptor CXCR3.
No effect was observed in monocytes. Whereas inhibition
of the cyclooxygenase pathway or the FLAP protein
showed no effect, blockade of 5-LO significantly down-
regulated CXCL10 protein levels. 5-LO mRNA was
detected in monocytes and in monocyte-derived macro-
phages. All tested cell types expressed 5-LO protein.
Conclusions: ML3000 effectively downregulates CXCR3
ligands. This study confirms that a thorough analysis of
the impact of a drug on its target cells cannot only reveal
unexpected properties of a substance, but also helps to
understand the underlying molecular mechanisms.
Accordingly, our data provide the basis for further clinical
studies testing the application of ML3000 in diseases
such as rheumatoid arthritis or multiple sclerosis.
ML3000 is an analogue of arachidonic acid and
thereby blocks the conversion of arachidonic acid
to prostaglandins by cyclooxygenases (COX) and
to leucotrienes by 5-lipoxygenases (5-LO).1 As
ML3000 tightly fits in the active site of the
enzymes COX 1, 2 and 5-LO, the recruitment
and processing of arachidonic acid is inhibited.2
This dual inhibition leads to an equal reduction of
prostaglandins and leucotrienes, which are potent
mediators in a variety of inflammatory diseases.
Accordingly, ML3000 showed good efficacy against
inflammation and hyperalgesia in various animal
models of joint inflammation.3 4 Furthermore, it
has been suggested that by single inhibition of the
COX pathway, the formation of leucotrienes is
enhanced due to a shunt mechanism in the
arachidonic acid metabolism, resulting in increased
gastrointestinal damage and ulceration.1 In accor-
dance with this hypothesis, the balanced reduction
of prostaglandins and leucotrienes by ML3000 lead
to a better gastrointestinal tolerability compared
with classical non-steroidal anti-inflammatory
drugs (NSAIDs) in human healthy volunteers.5
Recently, it was also described that a balanced,
dual inhibition could have a more favourable
cardiovascular profile than selective COX-2 inhibi-
tors.6
In previous reports, we suggested the use of
molecular biology methods in drug development
and assessment.7 8 The analysis of changes in gene
expression before and after treatment can possibly
reveal molecular mechanisms behind a clinically
observed side-effect or point to unexpected proper-
ties of a drug that might establish new indications.
In the present study, we analysed the impact of
ML3000 on gene expression in cultured, activated
synovial fibroblasts (SF) of patients with rheuma-
toid arthritis (RA). We found that the expression
of the chemokines CXCL10 (IP-10), CXCL11 (I-
TAC) and CXCL9 (Mig) was downregulated after
treatment. All three chemokines are ligands of the
chemokine receptor CXCR3. They have been
described to play a part in a variety of inflamma-
tory and autoimmune diseases and have repeatedly
been discussed as attractive new drug targets.9–11
The regulation of these chemokines has never been
described for either a COX, 5-LO or a dual
inhibitor. We found that this property of ML3000
is linked to the inhibition of 5-LO and is influenced
by the transcriptional regulation of 5-LO in
different cell systems.
MATERIALS AND METHODS
Cell culture and media
Synovial tissues from RA and osteoarthritis (OA)
patients undergoing joint replacement surgery
were minced and digested in 150 mg/ml dispase
II (Roche, Mannheim, Germany) at 37uC for
60 min. All patients with RA fulfilled the
American College of Rheumatology criteria for
the classification of RA. The SFs were then grown
in DMEM (Gibco Invitrogen, Basel, Switzerland)
supplemented with 10% heat inactivated fetal calf
serum (FCS), 50 IU/ml penicillin-streptomycin,
2 mM L-glutamine, 10 mM HEPES and 0.2%
fungicide (all Gibco Invitrogen). For experiments
cultured SFs were used after four to nine passages.
Peripheral blood mononuclear cells were iso-
lated from Buffy coats of healthy volunteers with
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Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Sweden)
gradient centrifugation. Peripheral blood monocytes were then
positively separated with CD14 microbeads (Miltenyi Biotec,
Auburn, CA, USA) according to the manufacturer’s protocol.
Monocyte-derived macrophages (MDMs) were generated by
treatment of the isolated peripheral blood monocytes with
15 ng/ml macrophage colony-stimulating factor (R&D Systems,
Minneapolis, MN, USA) every 48 h for 7 days. MDMs and
monocytes were cultivated in RPMI 1640 (Gibco Invitrogen)
supplemented with 10% FCS, 50 IU/ml penicillin–streptomy-
cin, 2 mM L-glutamine, 10 mM HEPES and 0.2% fungicide.
All cell cultures were maintained in a 5% CO2 humidified
incubator at 37uC.
Stimulation
ML3000 (Merckle GmbH, Blaubeuren, Germany) was recon-
stituted with DMSO to a stock concentration of 45 mg/ml,
naproxen to a concentration of 150 mg/ml, BWA4C to 1.4 mg/
ml and MK886 to 2.5 mg/ml (all Sigma, Basel, Switzerland).
The drugs were further diluted with 2% human serum albumin
(1:50), 0.5% human serum albumin (1:10), and with the
corresponding medium without antibiotics, fungicides and with
0.5% FCS to the final working concentration. For control,
DMSO alone was diluted correspondingly. Viability of RA SFs
(RASF) after treatment with the above-mentioned drugs was
assessed by trypan blue exclusion and by luminometric
measurement of adenosine triphosphate with the ViaLight
MDA Plus kit according to the manufacturer’s instructions
(Cambrex, Taufkirchen, Germany).
In the chosen working concentrations all the drugs showed
comparable effectiveness; ie, 3 mg/ml ML3000, 0.05 mg/ml
MK886 and 0.03 mg/ml BWA4C similarly reduced the produc-
tion of leucotriene B4 in MDMs by 60–65%, and 3 mg/ml
ML3000 and 30 mg/ml naproxen similarly reduced prostaglandin
E2 production in SFs by 85–90%. Leucotriene and prostaglandin
production was measured after stimulation with the calcium
ionophore A23187 (Sigma) (2.5 mM, 15 min) using ACE
Competitive Enzyme Immunoassay (Cayman Chemical, Ann
Arbor, MI, USA) according to the manufacturer’s instructions.
Absorption was measured at 405 nm and data were analysed
using the data analysis spreadsheet available from the Cayman
Chemical web page (http://www.caymanchem.com/app/
template/analysis%2CEIA.vm/a/z, accessed 10 June 2007). In
the concentrations used, ML3000 specifically inhibits of COX
and 5-LO, but has no effect on the activity of 12-LO or 15-LO
(communication with Stefan Laufer).
Cultured cells were pre-stimulated with 10 ng/ml tumour
necrosis factor (TNF)-a or 100 U/ml interferon (IFN) c (both
R&D Systems) for 24 h and then treated with the correspond-
ing drugs in addition with TNF-a or IFN-c as indicated for 48 h.
During treatment cells were cultivated in their respective
medium without antibiotics or fungicide, supplemented with
0.5% FCS.
Affymetrix gene chip
Total RNA from TNF-a stimulated RASF, incubated with or
without ML3000 (10 mg/ml) was isolated with the RNeasy
MiniPrep Kit (Qiagen, Basel, Switzerland) including treatment
with RNase-free DNase. The quality of the RNA was checked
with the Agilent 2100 Bioanalyser (Agilent Technologies, Palo
Alto, CA, USA). Double-stranded cDNA was synthesised from
5 mg RNA using the SuperScript cDNA synthesis customer kit
(Invitrogen, Basel, Switzerland). Convertion to biotin-labelled
cRNA was done with the BioArray HighYield RNA labeling kit
(Enzo Diagnostics, Farmingdale, NY, USA). The labelled RNA
was hybridised on human genome U133A oligonucleotide probe
arrays (Affymetrix, Santa Clara, CA, USA), according to
standard protocols. Data were normalised (set measurements
,0.01 to 0.01 and per chip normalisation to 50th percentile) and
analysed with GeneSpring microarray analysis software (Silicon
Genetics, Redwood City, CA, USA). Filters were set on a
fivefold regulation, flags had to be present or marginal in at least
one of two compared samples.
Real-time polymerase chain reaction
Total RNA was isolated with the RNeasy MiniPrep kit,
including treatment with RNase-free DNase (Qiagen) and
reverse transcribed using random hexamers and multiscribe
reverse transcriptase (both Applied Biosystems, Rotkreuz,
Switzerland). Non reverse transcribed samples were used as
negative controls. Quantification of mRNA was performed by
single-reporter Real-time polymerase chain reaction (PCR) using
the ABI Prism 7700 Sequence Detection system (Applied
Biosystems). Eukaryotic 18S rRNA levels, measured with a
pre-developed primer/probe system (Applied Biosystems) were
used as endogenous control for relative quantification. The
differences of the comparative threshold cycle (Ct) values of
sample and 18S cDNA were calculated (dCt). Relative expression
levels were calculated following the formula ddCt = dCt (sample
stimulated) – dCt (sample unstimulated), relative expression was
calculated using the expression 22ddCt. Only samples with a
difference of at least four cycles between cDNA and non-reverse,
transcribed samples were considered for calculations.
Primers were designed with Primer 3 software (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi, accessed 1 June
2007). Dissociation curve analysis for each SYBR green primer
pair and reaction was performed to verify specific amplification.
CXCL9: forward primer 59-GGC ATC ATC TTG CTG GTT
CT-39, reverse primer 59-TCA CTA CTG GGG TTC CTT GC-
39; CXCL10: forward primer 59-AAC CAG AGG GGA GCA
AAA TC-39, reverse primer 59-CTG TGT GGT CCA TCC TTG
G-39; CXCL11: forward primer 59-TGG CAA CAG TGC ACA
TAT TTC A-39, reverse primer 59-CAA ATT AAG ACC GGT
GCT GCT A-39.
Enzyme-linked immunoabsorbent assay
CXCL10 protein was detected in the supernatant using DuoSet
ELISA Development Systems (R&D Systems) according to the
manufacturer’s instructions. Absorption was measured at
450 nm and data were analysed using Revelation v4.22 software
(Dynex Technologies, Denkendorf, Germany).
Conventional polymerase chain reaction
Total RNA was isolated as described above for real-time PCR.
Conventional PCR was performed on a GenAmp PCR System
9700 (Applied Biosystems) with the following primer pairs and
protocols. 5-LO:12 forward primer 59-TAC ATC GAG TTC CCC
TGC TAC-39, reverse primer 59-GTT CTT TAC GTC GGT
GTT GCT-39; b-microglobulin forward primer 59-AAG ATT
CAG GTT TAC TCA CGT C-39, reverse primer 59-TGA TGC
TGC TTA CAT GTC TCG-39; 94uC 5 min, 35 cycles with 94uC
30 s, 57uC (for 5-LO)/55uC (for b-microglobulin) 30 s, 72uC 30 s
and a final elongation of 5 min with 72uC. Reaction products
were separated on a 1% agarose gel and signals were visualised
using ethidium bromide. As a negative control, PCR was carried
out in the absence of cDNA for each set of primers.
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Western blot
Cells were lysed in 26 Laemmli buffer, denaturated for 3 min at
95uC and separated on 10% SDS–PAGE. After transfer on to
Protran nitrocellulose transfer membranes (Schleicher & Schu¨ll,
Dassel, Germany) and blocking with 5% non-fat dry milk,
membranes were incubated with mouse anti-human 5-LO
antibodies (BD Transduction Laboratories, San Diego, CA, USA)
overnight at 4uC (dilution 1:250). Signals were visualised by
incubation with peroxidase-conjugated goat anti-mouse antibo-
dies (Jackson ImmunoResearch, West Grove, PA, USA) and
enhanced chemoluminescence system (Amersham Biosciences,
Otelfingen, Switzerland). For normalisation, membranes were
stripped and probed with mouse anti-human a-tubulin antibodies
(Sigma).
Statistical analysis
Values are presented as mean (SEM); n = number of stimula-
tions. Wilcoxon matched-pairs signed-ranks test was used for
statistical evaluation of the data by SPSS software; p,0.05 was
considered significant.
RESULTS
Downregulation of CXCR3 ligands by ML3000
To screen for genes that are regulated by treatment with
ML3000, we used an Affymetrix high-density oligonucleotide
array to compare gene expression in ML3000-treated RASF
versus untreated RASF, both stimulated with TNF-a. For the
stimulation of SF we chose TNF-a, as this is the main pro-
inflammatory cytokine found in joints of patients with RA.
After normalisation and filtering of the data, 28 genes were
shown to be more than fivefold downregulated after treatment
with ML3000 (data not shown). Most strikingly, seven (25%) of
these genes could be associated with IFN regulation. A dose-
dependent downregulation of this group was verified with Real-
time PCR. Two of the three CXCR3 ligands, namely CXCL10
and CXCL11 were among the genes that were regulated by
treatment with ML3000 (fig 1). Using Real-time PCR we also
confirmed the downregulation of CXCL9, the third ligand of the
CXCR3 receptor (fig 2a). CXCL9 expression was downregulated
to a lesser extent than CXCL10 or CXCL11, which could be the
reason why it did not appear on the chip. A time course of the
downregulation of CXCL9, -10 and -11 is shown in fig 2b. The
expression of all three chemokines was strongly induced by
TNF-a treatment in SF, in non-stimulated RASF the levels of
measured chemokines were under the detection limit. For all
further experiments, we used a concentration of 3 mg/ml ML3000,
as according to the manufacturing company this concentration
approximates the level of ML3000 measured in the joints of
patients using oral treatment (unpublished communication).
To see if the changes in CXCR3 ligand gene expression were
disease specific, we performed the same experiments using SF
from patients with OA. No disease-specific regulation by
ML3000 was detectable, the downregulation of all three
measured chemokines was in the same range as in RASF (fig 2c).
To analyse whether the effect of ML3000 is limited to
fibroblasts, we treated other cell types that are known to
express CXCL9, CXCL10 and CXCL11. In monocytes and
macrophages the main stimulus for the expression of CXCL9,
CXCL10 and CXCL11 is IFN-c. Therefore, we stimulated
monocytes and MDMs with IFN-c and treated them with
3 mg/ml ML3000. The effect of ML3000 between monocytes
and MDMs was different. Whereas the downregulation in
macrophages (MDMs) was similar to SF, only a small effect
could be seen in monocytes (fig 2d).
In the further analysis, we concentrated on CXCL10 with
regard to its well described role in a variety of pathological
status including RA. Even though also CXCL9 and CXCL11
seem to be important factors, their specific roles are much less
defined. Protein levels of CXCL10 were measured after treatment
with ML3000. The results confirmed the data obtained at the
mRNA level. Whereas 3 mg/ml ML3000 was enough to signifi-
cantly reduce CXCL10 production in SFs and MDMs, no
significant change could be observed in monocytes (fig 3).
Mechanisms of CXCR3 ligand regulation
To find out whether the blockade of the COX or the 5-LO
pathway is responsible for the described effects of ML3000, we
treated TNF-a stimulated RASF with the COX inhibitor
naproxen, the 5-LO inhibitor BWA4C and with the inhibitor
of the 5-LO activating protein (FLAP) MK886. The COX
inhibitor naproxen, had no effect on CXCL10 production by
TNF-a-stimulated RASF. Treatment with the FLAP inhibitor
only slightly reduced the production of CXCL10 protein in some
of the tested patient cells; therefore, no statistical significance
was reached. In contrast, downregulation of CXCL10 protein
levels after treatment with BWA4C was consistent and reached
statistical significance (fig 4). The combination of either 5-LO
inhibitor, BWA4C or MK886 with naproxen, had the same
effect on the production of CXCL10 as treatment with the 5-LO
inhibitors alone (n = 2; data not shown). Thereby, we concluded
that inhibition of CXCR3 ligand production by ML3000 must be
an effect, that is independent of its ability to block the COX
pathway, but is linked to its blockade of 5-LO.
Furthermore, mRNA and protein levels of 5-LO were measured.
We could detect a strong band for 5-LO mRNA in monocytes, only
a weak band in MDMs and no band was visible in SF (fig 5a). All
measured cell types had detectable levels of 5-LO protein, albeit
they were noticeably higher in monocytes compared with MDMs
or SF (fig 5b). Thus, we assume that different regulation of 5-LO
transcription and de novo synthesis in the analysed cell types could
Figure 1 Dose-dependent downregulation of genes after treatment
with ML3000. Rheumatoid arthritis synovial fibroblasts were treated with
1 mg/ml, 3 mg/ml, 9 mg/ml ML3000 or control reagent for 48 h (n = 5).
Expression levels were measured by real-time polymerase chain
reaction. Values are shown as mean percentage expression (SEM) as
compared with control.
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influence their sensitivity to treatment with ML3000 in respect to
the measured outcomes.
DISCUSSION
In the present study, we analysed the impact of ML3000 on the
transcriptome of SFs and found a previously unknown, anti-
inflammatory action. Thereby, we used microarray technology
as starting point for further experiments, characterising the
newly found properties in-depth. This simplified microarray
approach is not motivated by the generation of a complete gene
expression profile with clusters of genes that correlate with a
specific condition like in large-scale microarray experiments, but
serves as a basic screening technique for novel, unexpected
properties of a drug.
In our screening, we found evidence that ML3000 has an
impact on the transcriptional regulation of the chemokines
CXCL9, CXCL10 and CXCL11, all three ligands of CXCR3. This
effect was measurable on the mRNA as well as on the protein
level and was not restricted to SF or stimulation with TNF-a.
Chemokines in general play a fundamental role in the migration
of leucocytes to the site of inflammation. In the subgroup of
CXC chemokines, the CXCR3 ligands take an exceptional
position. While most CXC chemokines are clustered at
chromosome 4q12–13 and act on neutrophils, CXCL9,
CXCL10 and CXCL11 are found at 4q21.21 and mainly attract
T lymphocytes.13 High levels of CXCL9, 10 and 11 could be
detected in the synovial fluid of patients with RA.14–17 They are
mainly produced by fibroblasts and macrophages in the
synovium and are thought to be involved in the recruitment
of T helper 1 cells into the joint (for review18). CXCR3 ligands
were also found to play a crucial part in the accumulation of
activated lymphocytes in the brain of patients with multiple
sclerosis.19 Moreover, it is suggested that T cell attraction in
autoimmune liver disease, myasthenia gravis and acute renal
allograft rejection is mediated by CXCR3 and its ligands.20–22
Thus, this group of chemokines has been suggested as drug
targets in a variety of diseases.22 23 In fact, the application of a
decoy chemokine receptor DNA for the binding site of CXCR3
was shown to suppress the relapse of experimental autoimmune
encephalomyelitis in rats.24 Therefore, our data provide the basis
for further experiments testing the application and effectiveness
of ML3000 in diseases, such as multiple sclerosis and acute
allograft rejection, and thus a new field of indications for
ML3000 could be opened up.
We found that the ability of ML3000 to inhibit CXCR3 ligand
production does not stem from its ability to block the COX
pathway, but seems to be linked to the inhibition of 5-LO. In
accordance with our experiments, it was previously described in
macrophages and cancer cells that prostaglandin E2 can suppress
CXCL10 production and consequently, inhibition of the COX
pathway rather enhances production of CXCL10.25 26
Stimulation of SFs with prostaglandin E2 and/or leucotriene
B4 had no effect on the expression of either CXCL9, 10 or 11,
which remained under the detection limit (data not shown).
Additionally there was no difference between the tested 5-LO
inhibitors in their potential to inhibit leucotriene B4 synthesis in
Figure 2 (A) Downregulation of CXCL9
mRNA after treatment with ML3000 in
stimulated rheumatoid arthritis synovial
fibroblasts (RASF; n = 8). (B) Time
course of the effect of ML3000 on the
expression of CXCL9, 10 and 11 (n = 3).
Downregulation of CXCL9, CXCL10 and
CXCL11 mRNA after treatment with
ML3000 in stimulated (C) OA SF (n = 5),
(D) monocytes (n = 5) and monocyte-
derived macrophages (MDMs; n = 6).
Expression levels were measured by real-
time polymerase chain reaction. TNF,
tumour necrosis factor; IFN, interferon.
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monocytes. Therefore the downregulation of CXCR3 ligands is
probably independent of the role of 5-LO in leucotriene
biosynthesis. We assume that inhibition of the production of
this specific group of chemokines could be a direct effect of
inhibiting other functions of the 5-LO protein. Functions of 5-
LO beyond the leucotriene pathway have been suggested before
and are supported by studies showing 5-LO to localise at sites of
active gene transcription in the nucleus even in cells that are not
producing leucotrienes.27 By means of a yeast two-hybrid
system 5-LO was found to interact with the transforming
growth factor type b receptor-I-associated protein 1 (TRAP-1).
It was suggested that via TRAP-1, 5-LO is associated with the
activated transforming growth factor-b receptor and modulates
its signalling.28 However, up to now the association between the
expression of CXCL10 and transforming growth factor b
signalling in fibroblasts has not been described yet, and further
studies have to be conducted to elucidate these cellular
functions of 5-LO.
Regulation, localisation and translocation of 5-LO have been
found to be highly variable between different cell types.29 In
particular it has been shown that while monocytes express high
amounts of 5-LO mRNA, this production is lost during the
maturation to MDMs30. In resting cells 5-LO is stored, and only
upon activation translocated and bound to membranes.31 These
findings can explain why we could only detect mRNA for 5-LO
in monocytes, but not in MDMs or SFs. In contrast, stored 5-LO
protein could be found in all tested cell types. Inhibition of 5-LO
activity by blocking its active centre could possibly be overcome
in monocytes via increased de novo production.
In summary, we show that the COX/5-LO inhibitor ML3000
inhibits the production of the CXCR3 ligands CXCL10, CXCL9
and CXCL11. Furthermore, we found evidence for new cellular
roles of 5-LO. Our study proves that by analysing the molecular
impact of a drug on its target cells, off-target effects and their
underlying molecular mechanisms can be revealed. In our case,
off-target effects of the analysed drug turned out to be
beneficial, as CXCR3 ligands have repeatedly been suggested
as possible drug targets for a variety of inflammatory diseases.
Accordingly, animal and clinical studies testing the application
of ML3000 in diseases such as RA and multiple sclerosis or acute
allograft rejection should be taken into consideration. On the
other hand, off-target effects are often the cause of adverse side-
effects, which makes it even more important to include such
molecular studies early on in the development of a drug.
Figure 3 Regulation of CXCL10 protein
levels as measured by ELISA in
supernatants of stimulated rheumatoid
arthritis synovial fibroblasts (RASFs;
n = 7), osteoarthritis synovial fibroblasts
(OASF; n = 5), monocytes (n = 4) and
monocyte-derived macrophages (MDMs;
n = 6) after treatment with 3 mg/ml
ML3000. (A) Values are shown as mean
percentage expression (SEM) as
compared with control. *p,0.05.
(B) Levels of CXCL10 in each individual
measurement are shown before and after
treatment.
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Figure 4 Changes of CXCL10 protein levels in the supernatants of
stimulated rheumatoid arthritis synovial fibroblasts (RASFs) after
treatment with 30 mg/ml naproxen, 0.05 mg/ml MK886, 0.03 mg/ml
BWA4C and 3 mg/ml ML3000 as measured by ELISA (n = 5). All values
are shown as mean percentage expression (SEM) as compared with
control. *p,0.05.
Figure 5 (A) 5-LO mRNA expression in RASF (n = 4), OASF (n = 2),
monocytes (n = 5) and MDMs (n = 3). One representative polymerase
chain reaction is shown. (B) 5-LO protein (79 kDa) expression in cell
lysates of RASF, OASF, monocytes and MDMs. RASF, rheumatoid
arthritis synovial fibroblast; OASF, osteoarthritis synovial fibroblast;
5-LO, 5-lipoxygenase; MDMs, monocyte-derived macrophages.
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